Aurora Cannabis Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Aurora Cannabis Inc (ACB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Aurora Cannabis Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 370M vs 127M combined for its competitors (74.4% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs decelerating (-4.1%) for its tracked peer group.
- Profitability: Its -28.2% net margin compares with -218.1% for the peer group.
- Scale: Aurora Cannabis Inc ranks #6 of 37 companies by market capitalization in the Legal Cannabis industry, holding 3.1% of industry market cap.
- Peer revenue share: Aurora Cannabis Inc accounted for 92.4% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.37M compares with $0.48M for the peer group (0.8x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ACB Sales vs. its Competitors, Q4 2026
With a net margin of -28.18 %, Aurora Cannabis Inc achieved higher profitability than its competitors (-218.06 %).
Aurora Cannabis Inc generated 92.37 % of the combined sales of its peer group.
Aurora Cannabis Inc vs. its Competitors, Q4 2026
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Aurora Cannabis Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Aurora Cannabis Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Aurora Cannabis Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Aurora Cannabis Inc's competitor groups requires a Commercial License.
Aurora Cannabis Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Aurora Cannabis Inc | No | Yes | Yes | No |
| Competitors combined (20) | ||||
| High-Confidence Competitors (6) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 75.00 % (6 of 8) | 75.00 % (6 of 8) | 28.60 % (2 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ACB Stock Performance relative to its Competitors
ACB Stock Performance relative to High-Confidence Competitors
ACB Stock Performance relative to Similar-Size Competitors
ACB Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Lexaria Bioscience Corp | 282.9% | Outperformed |
| 2 | Intercure Ltd | 282.9% | Outperformed |
| 3 | High Tide inc | 282.9% | Outperformed |
| 4 | Organigram Global Inc | 282.9% | Outperformed |
| 5 | Igc Pharma Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Aurora Cannabis Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Aurora Cannabis Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Aurora Cannabis Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Aurora Cannabis Inc |
- | 369.53 |
 High Tide inc |
216.13 | 424.27 |
 Earth Science Tech Inc |
27.55 | 34.65 |
 Incannex Healthcare Inc |
26.46 | - |
 Zerostack Corp |
25.60 | 40.03 |
 Igc Pharma Inc |
18.96 | 1.10 |
| SUBTOTAL | 332.89 | 1,398.93 |
Sign in to see all competitors of Aurora Cannabis Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Aurora Cannabis Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Aurora Cannabis Inc's Competitors Named by the Company
Competitive relationships identified from Aurora Cannabis Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Aurora | Company report | 85% |
| Leafio | Company report | 85% |
| Montu Australia | Company report | 85% |
| Intercure Ltd | Company report | 85% |
| Akanda Corp | Company report | 85% |
| Can B Corp | Company report | 85% |
| Luminar Technologies Inc | Company report | 85% |
| Constellation Brands Inc | Company report | 85% |
| Clever Leaves Holdings Inc | Company report | 85% |
| Gb Sciences Inc | Company report | 85% |
| General Cannabis Corp | Company report | 85% |
| Greenlane Holdings Inc | Company report | 85% |
| Organigram Global Inc | Company report | 85% |
| Arax Holdings Corp | Company report | 85% |
| High Tide inc | Company report | 85% |
| Medicine Man Technologies inc | Company report | 85% |
| Groove Botanicals Inc | Company report | 85% |
| Nu med Plus Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Aurora Cannabis Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Aurora Cannabis Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Greenlane Holdings Inc | Wholesale or Distribution 100.00 % |
| Cannapharmarx Inc | Operating Segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Aurora Cannabis Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Aurora Cannabis Inc | - | 369,528 | -104,148 |
| High Tide inc | 216 | 707,110 | -61,193 |
| Earth Science Tech Inc | 28 | - | - |
| Incannex Healthcare Inc | 26 | - | -1,483,500 |
| Zerostack Corp | 26 | - | - |
| Igc Pharma Inc | 19 | 73,400 | -583,867 |
| PEERS TOTAL | 333 | 482,834 | -145,793 |
Sign in to see all peers for Aurora Cannabis Inc .
Aurora Cannabis Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Zerostack Corp | DE 92.55 % |
| Greenlane Holdings Inc | US 100.00 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Aurora Cannabis Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 24 companies in Aurora Cannabis Inc's industry classification, broader than the peer set above. Market cap in millions of $.Aurora Cannabis Inc ranks #6 of 24 companies by market capitalization in its industry, holding 3.06 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 2,315, indicating a moderately concentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Definium Therapeutics Inc | 3,360 | 35.67 % |
| 2 | Regencell Bioscience Holdings Limited | 2,606 | 27.66 % |
| 3 | Cronos Group Inc | 1,395 | 14.81 % |
| 4 | Sndl Inc | 346 | 3.68 % |
| 5 | Tilray Brands Inc | 1,234 | 5.2% |
| 6 | Aurora Cannabis Inc | 289 | 3.06 % |
| 7 | Canopy Growth Corporation | 1,234 | 5.2% |
| 8 | Usana Health Sciences Inc | 1,234 | 5.2% |
| 9 | Niagen Bioscience Inc | 1,234 | 5.2% |
| 10 | Mediwound Ltd | 1,234 | 5.2% |
Market cap and industry share for the rest of Aurora Cannabis Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-05.
Aurora Cannabis Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Definium Therapeutics Inc | 3,360 | 160.04 % |
| 2 | Regencell Bioscience Holdings Limited | 2,606 | -58.87 % |
| 3 | Cronos Group Inc | 1,395 | 54.29 % |
| 4 | Sndl Inc | 346 | -25.27 % |
| 5 | Tilray Brands Inc | 1,234 | 12.3% |
| 6 | Aurora Cannabis Inc | 289 | 15.42 % |
| 7 | Canopy Growth Corporation | 1,234 | 12.3% |
| 8 | Usana Health Sciences Inc | 1,234 | 12.3% |
| 9 | Niagen Bioscience Inc | 1,234 | 12.3% |
| 10 | Mediwound Ltd | 1,234 | 12.3% |
| 11 | Fitlife Brands Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Aurora Cannabis Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-05. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Aurora Cannabis Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Legal Cannabis industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (43 companies). See the full Legal Cannabis industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 28.33 % | 37.68 % (avg) | -9.4 pp |
| Operating Margin | -47.67 % | industry median | -43.3 pp |
| EBITDA Margin | -10.60 % | -1.95 % (avg) | -8.6 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 5.10 % (avg) | -5.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Aurora Cannabis Inc's Strategic Group Map
Aurora Cannabis Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Aurora Cannabis Inc's trailing-12-month revenue growth of 49.7% and operating margin of -47.7% compares with an average of 24.6% growth and -10.8% margin across its 8 closest peers by combined growth, margin and ROIC -- Aurora Cannabis Inc sits above that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Aurora Cannabis Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Aurora Cannabis Inc falls in the Dog quadrant: relative market share of 0.09x vs its largest competitor, in an industry growing revenue 0.8% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution. A caveat worth reading alongside this chart: Definium Therapeutics Inc alone holds 36% of this industry's market cap. In an industry this dominated by one leader, the framework will place nearly every OTHER company in "Dog" or "Question Mark" purely because relative share is measured against that leader, regardless of how strong those other companies actually are on their own fundamentals. Check the Profitability, Valuation and Financial Strength sections above before treating this quadrant label as a verdict.
Aurora Cannabis Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 2,315 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 5.10 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Aurora Cannabis Inc's dedicated Suppliers and Customers pages, not here.
Aurora Cannabis Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Aurora Cannabis Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Aurora Cannabis Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 14.2 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Operating margin 43.3 points below the industry median.
- Low relative market share vs the industry leader (0.09x).
Opportunities
- A meaningful share of competitors (63.20 %) show financial-distress signals, a possible opening to gain share.
Threats
- Industry dominated by Definium Therapeutics Inc , holding 35.67 % of industry market cap.
- Tracked peer group's revenue run-rate is broadly decelerating (-4.1% annualized).
Methodology: see Methodology: SWOT Analysis.
Aurora Cannabis Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Aurora Cannabis Inc | 0.97 | 5.94 | - |
| High Tide inc | 0.48 | 1.37 | 0.13 |
| Earth Science Tech Inc | 0.36 | 1.35 | 0.01 |
| Incannex Healthcare Inc | 18.92 | 20.72 | - |
| Zerostack Corp | 0.67 | 1.33 | 0.38 |
| Igc Pharma Inc | 0.21 | 0.74 | 0.16 |
Sign in to see all peers for Aurora Cannabis Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Aurora Cannabis Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Aurora Cannabis Inc | Q1 2026 | +49.7 % | - |
| High Tide inc | Q3 2025 | +10.5 % | - |
| Earth Science Tech Inc | Q2 2026 | +11.6 % | +51.2 % |
| Incannex Healthcare Inc | Q2 2026 | - | - |
| Zerostack Corp | Q2 2026 | +40.7 % | - |
| Igc Pharma Inc | Q2 2026 | -19.7 % | - |
| PEERS TOTAL | +52.7 % | - |
Sign in to see all peers for Aurora Cannabis Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Aurora Cannabis Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Aurora Cannabis Inc | Q1 2026 | - | - |
| High Tide inc | Q3 2025 | +12.5 % | +19.3 % |
| Earth Science Tech Inc | Q2 2026 | +37.5 % | -89.9 % |
| Incannex Healthcare Inc | Q2 2026 | - | - |
| Zerostack Corp | Q2 2026 | +32.5 % | - |
| Igc Pharma Inc | Q2 2026 | +23.3 % | +108.2 % |
Sign in to see all peers for Aurora Cannabis Inc .
Aurora Cannabis Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Aurora Cannabis Inc | - | - | - |
| High Tide inc | - | - | - |
| Earth Science Tech Inc | 44.02% | 64.38% | 66.17% |
| Incannex Healthcare Inc | - | - | - |
| Zerostack Corp | - | - | - |
| Igc Pharma Inc | - | - | - |
Sign in to see all peers for Aurora Cannabis Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Aurora Cannabis Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Aurora Cannabis Inc | - | - |
| High Tide inc | - | 0.51 |
| Earth Science Tech Inc | 19.00 | 0.80 |
| Incannex Healthcare Inc | - | - |
| Zerostack Corp | - | 0.64 |
| Igc Pharma Inc | - | 17.22 |
| PEERS AVERAGE | - | 0.24 |
Sign in to see all peers for Aurora Cannabis Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.